Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Powdered Intrawound Vancomycin in Open Fractures
NCT06504992Phase 4Not yet recruiting
- Sponsor
- University of Manitoba
- Start
- Nov 2024
- Primary completion
- Sep 2028
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of vancomycin in surgical site infection (SSI) (2 arms), sponsored by University of Manitoba. Primary endpoint: Deep surgical site infection at 6 months. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
vancomycin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT06504992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504992.